H. Lee Moffitt Cancer Center and Research Institute
This phase 1, single-center, open-label dose-escalation study will evaluate the safety, tolerability, and immune reconstitution effects of efineptakin alfa (rhIL-7-hyFc, NT-I7) administered after allogeneic hematopoietic cell transplantation (allo-HCT) in participants receiving post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis.
Inclusion Criteria: * First allogeneic HCT with peripheral blood as the only graft source used for allo HCT. * Diagnosis of hematologic malignancy eligible for allo-HCT. * Only patients with plan for post-transplant cyclophosphamide based GVHD prophylaxis are eligible. * Eligible donors include matched-related, matched-unrelated, mismatched unrelated, and HLA-haploidentical relatives with a shared HLA haplotype with the patient, determined by high-resolution DNA typing at HLA-A, -B, -C, and -DRB1 loci per standardof care practice as documented in the medical record. * Granulocyte-colony stimu…
Single intramuscular administration on Day +60 after allo-HCT. Dose escalation includes 240 μg/kg, 480 μg/kg, and 720 μg/kg.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.